Latest News
& Press Releases
Browse the latest news from BioSpace, and press releases from around the industry. Want to filter by date, keyword, and more? Search here.
TOP STORIES
The FDA informed Moderna that it would need more time to evaluate the company’s Emergency Use Authorization (EUA) submission for its COVID-19 vaccine for adolescents 12 to 17 years of age.
GlaxoSmithKline denied reports that they were interested in acquiring Canada’s Aurinia Pharmaceuticals, although some reports claim they are preparing to bid.
One year after snagging $310 million in a financing round, LianBio raised $325M in its initial public offering. Its stock begins selling today on Nasdaq under the ticker symbol “LIAN.”
Inovio shares are down about 2% in premarket trading after cancellation reports of a DNA cancer vaccine collab with AstraZeneca.
Researchers found that those who took either the once-a-month or once-every-two-month doses experienced longer periods before relapsing.
The National Institutes of Health has removed a notice aimed at encouraging grant proposals from minority scientists from three separate institutes.
As the world marks a grim milestone of 5 million COVID-19 deaths, public health officials are keeping a close watch on a substrain of the Delta variant.
Under the agreement, Merck can use Synthekine’s surrogate cytokine agonist platform to discover, develop, and sell new cytokine-based treatments for up to two cytokine targets.
The decision came after Avoro Capital Advisors, which owns a 7% stake in Acceleron, posted its objections to the deal.
BlueSphere Bio aims to overcome challenges in the CAR T space with a precision approach to T cell therapy.
Scemblix is the first-in-class FDA-approved treatment for adult patients diagnosed with Philadelphia chromosome-positive chronic myeloid leukemia.
This lipid-based system is able to tightly target antigen-presenting cells and thus trigger a rapid, persistent and robust T cell response against various cancers.